Molbio Diagnostics Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹768 - ₹807
- Lot size
- 18 shares
- Issue amount
- ₹939.7 cr
- Total subscription
- 70.26×
- Opens
- 10 Aug 2026
- Closes
- 12 Aug 2026
- Allotment
- 13 Aug 2026
- Listing
- 17 Aug 2026
Offer at a glance
Issue overview
- Issue size
- 1,16,46,246 shares
- Face value
- ₹1 per share
- Minimum investment
- ₹13,824
- Fresh issue
- ₹200 cr
- Offer for sale
- ₹742.45 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,526
- Issue type
- Bookbuilding IPO
- Shares before issue
- 11,27,59,750
- Shares after issue
- 11,52,39,996
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 18 | ₹14,526 |
| sHNI | 14 | 252 | ₹2,03,364 |
| bHNI | 69 | 1,242 | ₹10,02,294 |
Share reservation
Subscription & GMP
Subscription by category
Reported 12 Aug 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 2,26,056 | 25,24,586 |
| EMPLOYEES | 0 | 8,879 |
| HNIs(10L +) | 4,613 | 46,455 |
| HNIs (2-10L) | 2,307 | 1,06,589 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 187.64 | 34,973.94 |
| FIIs | 0 | 13,864.61 |
| FIs | 0 | 16,837.59 |
| Mutual Funds | 0 | 1,936.76 |
| Others | 0 | 2,334.97 |
| RETAIL | 328.37 | 4,254.45 |
| HNIs 2+ | 46.91 | 2,240.56 |
| HNIs 10+ | 93.82 | 4,767.48 |
| EMPLOYEES | 1.66 | 21.99 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 14.77 | 12.87 | 9.05 |
| ROE | 0 | 0 | 0 |
| ROCE | 0 | 0 | 0 |
| RONW | 14.55 | 15.23 | 12.62 |
| PRE IPO(PE) | 55.43 | 0 | 0 |
| POST IPO(PE) | 56.67 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Poly Medicure Limited | 52.61 | 0 | 5 | 306.45 | 10.37 | 31.79 |
| Dr. Lal PathLabs Limited | 62.2 | 0 | 10 | 145 | 20.78 | 30.24 |
| Metropolis Healthcare Limited | 63.72 | 0 | 2 | 72.98 | 12.56 | 9.19 |
| Vijaya Diagnostics Centre Limited | 81.02 | 0 | 1 | 93.02 | 18.07 | 16.81 |
| Molbio Diagnostics Limited | 55.43 | 0 | 1 | 101.51 | 14.55 | 14.77 |
Company information
Company profile
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Strengths
- Innovative Diagnostic Technology: Company nu flagship molecular testing platform rapid ane accurate diagnosis aape che, je healthcare sector ma strong differentiation create kare che.
- Recurring Consumable Revenue: Devices install thaya pachhi test kits ni regular demand ave che, je company ne stable ane repeat income aape che.
- Strong Financial Growth: Recent years ma revenue ane profit ma fast growth joi male che, je business scalability ane demand darshave che.
Risk factors
- High Dependence on Government Orders: Revenue no moto hissa government ane institutional clients mathi ave che, je policy changes thi impact thai shake che.
- Product Concentration Risk: Company nu major revenue limited diagnostic tests (especially TB related) par dependent che, je diversification risk create kare che.
- Working Capital Intensive: Inventory ane operations maintain karva ma heavy working capital joiye, je cash flow par pressure muki shake che.
Promoters
Sriram Natarajan
Dr. Chandrasekhar Bhaskaran Nair
Sangeetha Sriram
Shiva Sriram
Sowmya Sriram
Exxora Trading LLP
Registrar & documents
Lead manager
IIFL Capital Services Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company, Motilal Oswal Investment Advisors Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
+91 8326724888
[email protected]Company website ↗Understanding MOLBIO IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.